Due to inelastic demand, medical businesses are nevertheless robust. On top of it, given the increasing prevalence of chronic diseases, the aging population, and rising health awareness, new drugs and solutions are in line for development at full tilt. Moreover, with rapid technological advancements, the medical industry is expected to witness significant growth in the near future.
Therefore, we think it could be wise to buy fundamentally sound equities like Novo Nordisk A/S (NVO), AmerisourceBergen Corporation (ABC), Cardinal Health, Inc. (CAH), and Haemonetics Corporation (HAE) due to their excellent vitals.
